Background Newborn screening for medium- and very long-chain acyl-CoA dehydrogenase (MCAD and VLCAD, respectively) deficiency, using acylcarnitine profiling with tandem mass spectrometry, has increased the number of patients with fatty acid oxidation disorders due to the identification of additional milder, and so far silent, phenotypes. However, especially for VLCADD, the acylcarnitine profile can not constitute the sole parameter in order to reliably confirm disease. Therefore, we developed a new liquid chromatography tandem mass spectrometry (LC-MS/MS) method to rapidly determine both MCAD- and/or VLCAD-activity in human lymphocytes in order to confirm diagnosis. Methodology LC-MS/MS was used to measure MCAD- or VLCAD-catalyzed production of enoyl-CoA and hydroxyacyl-CoA, in human lymphocytes. Principal Findings VLCAD activity in controls was 6.95±0.42 mU/mg (range 1.95 to 11.91 mU/mg). Residual VLCAD activity of 4 patients with confirmed VLCAD-deficiency was between 0.3 and 1.1%. Heterozygous ACADVL mutation carriers showed residual VLCAD activities of 23.7 to 54.2%. MCAD activity in controls was 2.38±0.18 mU/mg. In total, 28 patients with suspected MCAD-deficiency were assayed. Nearly all patients with residual MCAD activities below 2.5% were homozygous 985A>G carriers. MCAD-deficient patients with one other than the 985A>G mutation had higher MCAD residual activities, ranging from 5.7 to 13.9%. All patients with the 199T>C mutation had residual activities above 10%. Conclusions Our newly developed LC-MS/MS method is able to provide ample sensitivity to correctly and rapidly determine MCAD and VLCAD residual activity in human lymphocytes. Importantly, based on measured MCAD residual activities in correlation with genotype, new insights were obtained on the expected clinical phenotype.
References
[1]
Wanders RJ, Vreken P, den Boer ME, Wijburg FA, van Gennip AH, et al. (1999) Disorders of mitochondrial fatty acyl-CoA beta-oxidation. J Inherit Metab Dis 22: 442–487.
[2]
Arnold GL, Van HJ, Freedenberg D, Strauss A, Longo N, et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96: 85–90.
[3]
Spiekerkoetter U, Lindner M, Santer R, Grotzke M, Baumgartner MR, et al. (2009) Treatment recommendations in long-chain fatty acid oxidation defects: consensus from a workshop. J Inherit Metab Dis.
[4]
Schulze A, Lindner M, Kohlmuller D, Olgemoller K, Mayatepek E, et al. (2003) Expanded newborn screening for inborn errors of metabolism by electrospray ionization-tandem mass spectrometry: results, outcome, and implications. Pediatrics 111: 1399–1406.
[5]
Schymik I, Liebig M, Mueller M, Wendel U, Mayatepek E, et al. (2006) Pitfalls of neonatal screening for very-long-chain acyl-CoA dehydrogenase deficiency using tandem mass spectrometry. J Pediatr 149: 128–130.
[6]
Browning MF, Larson C, Strauss A, Marsden DL (2005) Normal acylcarnitine levels during confirmation of abnormal newborn screening in long-chain fatty acid oxidation defects. J Inherit Metab Dis 28: 545–550.
[7]
Leonard JV, Dezateux C (2009) Newborn screening for medium chain acyl CoA dehydrogenase deficiency. Arch Dis Child 94: 235–238.
[8]
Arnold GL, Van HJ, Freedenberg D, Strauss A, Longo N, et al. (2009) A Delphi clinical practice protocol for the management of very long chain acyl-CoA dehydrogenase deficiency. Mol Genet Metab 96: 85–90.
[9]
Liebig M, Schymik I, Mueller M, Wendel U, Mayatepek E, et al. (2006) Neonatal screening for very long-chain acyl-coA dehydrogenase deficiency: enzymatic and molecular evaluation of neonates with elevated C14:1-carnitine levels. Pediatrics 118: 1065–1069.
[10]
Woldegiorgis G, Spennetta T, Corkey BE, Williamson JR, Shrago E (1985) Extraction of tissue long-chain acyl-CoA esters and measurement by reverse-phase high-performance liquid chromatography. Anal Biochem 150: 8–12.
[11]
Andresen BS, Bross P, Udvari S, Kirk J, Gray G, et al. (1997) The molecular basis of medium-chain acyl-CoA dehydrogenase (MCAD) deficiency in compound heterozygous patients: is there correlation between genotype and phenotype? Hum Mol Genet 6: 695–707.
[12]
Powell PJ, Lau SM, Killian D, Thorpe C (1987) Interaction of acyl coenzyme A substrates and analogues with pig kidney medium-chain acyl-coA dehydrogenase. Biochemistry 26: 3704–3710.
[13]
Davidson B, Schulz H (1982) Separation, properties, and regulation of acyl coenzyme A dehydrogenases from bovine heat and liver. Arch Biochem Biophys 213: 155–162.
Maier EM, Liebl B, Roschinger W, Nennstiel-Ratzel U, Fingerhut R, et al. (2005) Population spectrum of ACADM genotypes correlated to biochemical phenotypes in newborn screening for medium-chain acyl-CoA dehydrogenase deficiency. Hum Mutat 25: 443–452.
[16]
Andresen BS, Dobrowolski SF, O'Reilly L, Muenzer J, McCandless SE, et al. (2001) Medium-chain acyl-CoA dehydrogenase (MCAD) mutations identified by MS/MS-based prospective screening of newborns differ from those observed in patients with clinical symptoms: identification and characterization of a new, prevalent mutation that results in mild MCAD deficiency. Am J Hum Genet 68: 1408–1418.
[17]
Wanders RJ, Ijlst L (1992) Fatty acid beta-oxidation in leukocytes from control subjects and medium-chain acyl-CoA dehydrogenase deficient patients. Biochim Biophys Acta 1138: 80–84.
[18]
Aliefendioglu D, Dursun A, Coskun T, Akcoren Z, Wanders RJ, et al. (2007) A newborn with VLCAD deficiency Clinical, biochemical, and histopathological findings. Eur J Pediatr.
[19]
Voermans NC, van Engelen BG, Kluijtmans LA, Stikkelbroeck NM, Hermus AR (2006) Rhabdomyolysis caused by an inherited metabolic disease: very long-chain acyl-CoA dehydrogenase deficiency. Am J Med 119: 176–179.
[20]
Niezen-Koning KE, Chapman TE, Mulder IE, Smit GP, Reijngoud DJ, et al. (1991) Determination of medium chain acyl-CoA dehydrogenase activity in cultured skin fibroblasts using mass spectrometry. Clin Chim Acta 199: 173–184.
[21]
Duran M, Cleutjens CB, Ketting D, Dorland L, de Klerk JB, et al. (1992) Diagnosis of medium-chain acyl-CoA dehydrogenase deficiency in lymphocytes and liver by a gas chromatographic method: the effect of oral riboflavin supplementation. Pediatr Res 31: 39–42.
[22]
Chace DH, Hillman SL, Van Hove JL, Naylor EW (1997) Rapid diagnosis of MCAD deficiency: quantitative analysis of octanoylcarnitine and other acylcarnitines in newborn blood spots by tandem mass spectrometry. Clin Chem 43: 2106–2113.
